ImmunityBio FY2026 EPS Estimate Decreased by HC Wainwright

Key Points

• HC Wainwright has lowered its FY2026 EPS estimate for ImmunityBio from ($0.26) to ($0.29), while maintaining a "Buy" rating and a price target of $8.00.
• Despite the downgrade, the average rating for ImmunityBio remains at "Buy," with a consensus target price of $12.25 across several brokerages.
• Institutional investors have recently shown increased interest in ImmunityBio, acquiring new positions worth approximately $28,000 to $30,000 in the second quarter.

ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) - HC Wainwright dropped their FY2026 EPS estimates for shares of ImmunityBio in a report released on Wednesday, August 6th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($0.29) per share for the year, down from their prior forecast of ($0.26). HC Wainwright has a "Buy" rating and a $8.00 price objective on the stock. The consensus estimate for ImmunityBio's current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for ImmunityBio's FY2027 earnings at ($0.10) EPS and FY2028 earnings at $0.11 EPS.

Several other brokerages have also recently commented on IBRX. Piper Sandler raised ImmunityBio from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $4.25 to $5.00 in a report on Tuesday, May 20th. D. Boral Capital reaffirmed a "buy" rating and set a $30.00 target price on shares of ImmunityBio in a research note on Tuesday. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, ImmunityBio currently has an average rating of "Buy" and an average target price of $12.25.

ImmunityBio Trading Up 0.0%

IBRX traded up $0.00 on Friday, reaching $2.41. The company had a trading volume of 1,414,565 shares, compared to its average volume of 7,632,924. The company has a market capitalization of $2.13 billion, a P/E ratio of -5.01 and a beta of 0.12. The company has a fifty day moving average of $2.78 and a 200-day moving average of $2.83. ImmunityBio has a one year low of $1.83 and a one year high of $7.48.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). The business had revenue of $26.43 million during the quarter, compared to the consensus estimate of $21.95 million.

Institutional Investors Weigh In On ImmunityBio

Several hedge funds and other institutional investors have recently made changes to their positions in IBRX. Financial Enhancement Group LLC bought a new position in ImmunityBio in the 2nd quarter worth approximately $28,000. Summit X LLC acquired a new position in ImmunityBio during the 2nd quarter valued at $28,000. Thrive Wealth Management LLC bought a new stake in ImmunityBio in the 1st quarter valued at $30,000. Slow Capital Inc. acquired a new stake in ImmunityBio in the 1st quarter worth $30,000. Finally, Compound Planning Inc. bought a new position in shares of ImmunityBio during the 1st quarter worth about $30,000. 8.58% of the stock is owned by institutional investors and hedge funds.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.